Literature DB >> 1380031

Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line.

M Azuma1, M Cayabyab, D Buck, J H Phillips, L L Lanier.   

Abstract

NK cells and certain CTL can recognize and lyse targets without restriction by the MHC. NK cells do not express CD3/TCR complexes and the membrane receptors participating in MHC-unrestricted cytotoxicity are largely unknown. We demonstrate that YT2C2, a human NK leukemia cell line, expresses the CD28 differentiation Ag and can spontaneously lyse both murine and human cell lines expressing B7, a B cell- activation Ag that is a ligand for CD28. The participation of CD28/B7 interactions in MHC-unrestricted cytotoxicity mediated by YT2C2 cells was demonstrated by correlation of target sensitivity with levels of B7 expression, inhibition of cytotoxicity by anti-CD28 or anti-B7 mAb, and by making both murine and human cell lines susceptible to YT2C2-mediated lysis by genetic transfection with expression vectors containing B7 cDNA. However, CD28/B7 interactions alone were insufficient to initiate cytotoxicity. mAb inhibition experiments and selection of CD54- (intercellular adhesion molecule-1) deficient B cell targets indicated that CD11a/18 (lymphocyte function-associated Ag-1) also cooperated in CD28/B7-dependent cytotoxicity. The requirement for both CD28/B7 and lymphocyte function-associated Ag-1/intercellular adhesion molecule-1 interactions in YT2C2-mediated MHC-unrestricted cytotoxicity was confirmed by demonstrating that efficient lysis of murine L cells required cotransfection with both B7 and intercellular adhesion molecule-1. These findings support the concept that MHC-unrestricted cytotoxicity may not be due to a unique receptor, but may result from interactions between an appropriate array of "adhesion" molecules with their ligands.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380031

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation.

Authors:  L Coscoy; D Ganem
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes.

Authors:  Y Amakata; Y Fujiyama; A Andoh; K Hodohara; T Bamba
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 3.  Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma.

Authors:  Christopher A Hunter; Linda A Lieberman; Nicola Mason; Marion Pepper; Sarah L Sague; Cristina Tato; Valerie Zediak
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.

Authors:  P A Lando; M Dohlsten; G Hedlund; T Brodin; D Sansom; T Kalland
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

5.  Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.

Authors:  A Porgador; O Mandelboim; N P Restifo; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Kinetics of transcription factors regulating the RANTES chemokine gene reveal a developmental switch in nuclear events during T-lymphocyte maturation.

Authors:  B D Ortiz; A M Krensky; P J Nelson
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

7.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

8.  Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Authors:  Michelle K Gleason; Michael R Verneris; Deborah A Todhunter; Bin Zhang; Valarie McCullar; Sophia X Zhou; Angela Panoskaltsis-Mortari; Louis M Weiner; Daniel A Vallera; Jeffrey S Miller
Journal:  Mol Cancer Ther       Date:  2012-10-17       Impact factor: 6.261

9.  Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells.

Authors:  F F Fagnoni; M Takamizawa; W R Godfrey; A Rivas; M Azuma; K Okumura; E G Engleman
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

Review 10.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.